8 results
Primary objectives:To determine the objective tumor response (CR + PR) after 3 weeks of erlotinibSecondary objectives: To describe predictive markers for response:- radiological response (FDG-PET/CT)- EGFR mutations (HER1)To determine (diseasefree)…
To investigate the efficacy (and the toxicity) of Glivec in systemic sclerosis by examining clinical outcomes (clinical and laboratory findings).
Primary:•Efficacy of combination of erlotinib and sorafenib as determined by the rate of no progression at 6 weeks.•Determination of the impact of concomitant administration of sorafenib on the pharmacokinetics (PK) of erlotinibSecondary:•Efficacy…
The primary objective of this study is to evaluate whether surgery of residual disease in patients iwth advanced GIST responding to Imatinib improves the progression free survival.The secondary objective is to correlate the pharmacokinetics of…
Primary objective: Efficacy of erlotinib plus bevacizumab subsequent to the combination of carboplatin, paclitaxel and bevacizumab as determined by the maximum achieved disease control rate (DCR, complete response, partial response, or stable…
The purpose of this clinical trial is to test whether treatment of patients with NSCLC with erlotinib plus sunitinib is better than treatment with erlotinib plus placebo. All patients enrolling in this study will receive treatment with erlotinib.
Primary: To characterize the pharmacokinetics of imatinib in pediatric patients age 1 to less than 4 years via appropriate integrated PBPK and pop PK approaches
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.